You searched for Ibrutinib - Page 4 of 52

ASH 2022: Dr. Carsten Niemann with an Update on Fixed-Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL) in the GLOW Study

January 6, 2023

Fixed-duration ibrutinib plus venetoclax provides an overall survival advantage and better sustained progression-free survival regardless of measurable residual disease (MRD) status compared with chlorambucil plus obinutuzumab as a first-line treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

ASH 2022: Dr. Jennifer Brown on Zanubrutinib vs. Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL / SLL)

December 29, 2022

In this interview, Dr. Brian Koffman interviewed Dr. Jennifer Brown, Director of the CLL Center at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. They discussed the ALPINE trial, a phase 3 clinical trial directly comparing the efficacy of zanubrutinib vs. ibrutinib in patients with relapsed/refractory CLL / SLL.

ASH 2021: Dr. Talha Munir on Measurable Residual Disease After Fixed-Duration Ibrutinib plus Venetoclax

September 1, 2022

We discuss the latest results from the GLOW study, a phase 3 clinical trial which compared fixed-duration ibrutinib + venetoclax with chemoimmunotherapy (chlorambucil + obinutuzumab) as a first-line treatment.

ASH 2021: Dr. John Seymour on Side Effects of Acalabrutinib vs. Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

September 1, 2022

We discuss updated safety results from the ELEVATE R/R study, which is the first study comparing acalabrutinib with ibrutinib head-to-head in patients with relapsed/refractory CLL.

ASCO 2022: Four-year Follow-Up From a Phase 2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

August 25, 2022

ASCO 2022: Four-year Follow-Up From a Phase 2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL. This is a powerful combination with impressively durable responses in both TN and R/R patients.

ASCO 2022: Fixed-duration (FD) Ibrutinib (I) + Venetoclax (V) for First-Line (1L) Treatment (tx) of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Three-Year Follow-Up from the FD Cohort of the Phase 2 CAPTIVATE Study

August 25, 2022

At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, Dr. Bill Wierda of MDACC presented the follow-up three-year data of the fixed duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (treatment) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

ASH 2021 – Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or After Progression on Sequential I and V (Double Refractory)

July 13, 2022

Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double Refractory)

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

June 30, 2022

While this oral medication has dramatically improved the treatment of chronic lymphocytic leukemia/small lymphocytic leukemia (CLL / SLL), there is concern about the risk of heart or cardiovascular (CV) adverse effects due to off-target kinase inhibition.

ASH 2021: Dr. Jennifer Woyach on a Clinical Trial in Progress with Combination Ibrutinib, Venetoclax, and Obinutuzumab

June 2, 2022

Discussion of a phase 3 clinical trial in progress, investigating the efficacy of the triple combination of ibrutinib plus venetoclax and obinutuzumab with response-dependent discontinuation.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: Ibrutinib – Page 4

ASH 2022: Dr. Carsten Niemann with an Update on Fixed-Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL) in the GLOW Study

ASH 2022: Dr. Jennifer Brown on Zanubrutinib vs. Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL / SLL)

ASH 2021: Dr. Talha Munir on Measurable Residual Disease After Fixed-Duration Ibrutinib plus Venetoclax

ASH 2021: Dr. John Seymour on Side Effects of Acalabrutinib vs. Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

ASCO 2022: Four-year Follow-Up From a Phase 2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

ASCO 2022: Fixed-duration (FD) Ibrutinib (I) + Venetoclax (V) for First-Line (1L) Treatment (tx) of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Three-Year Follow-Up from the FD Cohort of the Phase 2 CAPTIVATE Study

ASH 2021 – Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or After Progression on Sequential I and V (Double Refractory)

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

ASH 2021: Dr. Jennifer Woyach on a Clinical Trial in Progress with Combination Ibrutinib, Venetoclax, and Obinutuzumab

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT